Immunotherapy in Head and Neck Cancer After Failure of Definitive Therapy.

Published Date: 12 Apr 2024

In a phase III trial, atezolizumab did not improve event-free survival when compared to placebo.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Children with the "Failure to Launch" Syndrome in Adulthood Have New Hope.

2.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

3.

Women who miss their first mammogram face higher risk of breast cancer death, study finds

4.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.

5.

Financial hardship common in patients with cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot